drugset / Trial / NCT06422624
A Study to Evaluate Safety, Tolerability and pK of Semaglutide ER Injectable Suspension in Healthy, Adult Human Subjects
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of the trail is to evaluate the safety, tolerability and pharmacokinetics of a single escalated doses of semaglutide extended-release injectable suspension in healthy adult, human study participants under fasting condition.
Timeline
- Start
- 2024-08
- Primary completion
- 2024-11
- Completion
- 2024-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Semaglutide | Peptide | 1 mg | Subcutaneous |
| Subject | Semaglutide | Peptide | 4 mg | Subcutaneous |
| Subject | Semaglutide | Peptide | 8 mg | Subcutaneous |